Endometriosis is a systemic inflammatory disease known to increase the risk of cardiovascular disease. The inducible form of cyclooxygenase (COX), COX-2, is an inflammatory enzyme upregulated in endometriosis with COX …
Endometriosis is an estrogen-dependent, progesterone-resistant gynecological disorder, with dysmenorrhea being the most common manifestation.
T. Shokeir, and S. Mousa, "A Randomized, Placebo-Controlled, Double-Blind Study of Hysteroscopic-Guided Pertubal Diluted Bupivacaine Infusion For Endometriosis-Associated Chronic Pelvic Pain," International Journal of Gynecology & Obstetrics 130, no. 3 …
Endometriosis is a non-malignant, estrogen-dependent chronic inflammatory disorder that affects 10-15% of women during their reproductive years. Emerging evidence highlights the undeniable role of oxidative stress in the etiopathogenesis of …
People with endometriosis report consuming cannabis to manage their endometriosis symptoms, however, its efficacy has not been established in clinical studies. This study aimed to determine the feasibility, acceptability, and …
We studied the effect nanomicelle curcumin on oxidative stress markers, pro-inflammatory cytokines, and assisted reproductive techniques (ART) outcomes in endometriosis cases. This randomized controlled trial was conducted on 50 women …
Women with endometriosis, an inflammatory disease, are at increased risk of cardiovascular disease and demonstrate impaired microvascular endothelial function, characterized by reduced nitric oxide (NO)-mediated vasodilation. In some clinical cohorts, …
The purpose of this review is to consider current ideas about psychophysiology of chronic pelvic pain (CPP) in external genital endometriosis (GE), as well as the impact of the psychoemotional …
Background/Objectives: Endometriosis is a chronic condition that affects 6-10% of women of reproductive age, with pain and infertility being its primary symptoms. The most common aspects of pain are overall …
To evaluate the efficacy and safety of the estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) combination in a cyclic regimen in Japanese women with primary and secondary dysmenorrhea.